DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)

Rhea-AI Summary

Daxor Corporation (Nasdaq: DXR) will exhibit at the MedAxiom CV Transforum Fall’22 Conference in Austin, TX, from October 6-8, 2022. This conference gathers cardiovascular leaders to enhance patient care. Daxor's blood volume analysis (BVA) technology shows significant improvements in patient outcomes, including an 82% reduction in 30-day mortality. Daxor recently partnered with MedAxiom to promote BVA adoption among its clinical members. The company's innovations aim to optimize fluid management, enhancing healthcare delivery.

Positive

• Daxor's BVA technology demonstrates strong clinical outcomes: 82% reduction in 30-day mortality, 86% in 1-year mortality, 56% in 30-day readmissions.
• Partnership with MedAxiom aims to enhance awareness and adoption of BVA technology among cardiovascular professionals.

Negative

• None.

The Premier Event For The Cardiovascular Industry's Leading Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically Improve Their Business and Patient-Care Outcomes

Oak Ridge, TN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting for the first time at the MedAxiom CV Transforum Fall’22 Conference being held at the JW Marriott in Austin, TX from October 6-8, 2022. The CV Transforum conference unites cardiovascular thought leaders from across the country to transform cardiovascular care together with leading industry innovators.

Daxor recently announced in July that it has entered an industry partnership with MedAxiom, an American College of Cardiology company, to amplify awareness and adoption of Daxor’s blood volume analysis (BVA) technology among MedAxiom’s clinical members.

“We are delighted to attend CV Transforum for the first time, bringing Daxor’s innovative BVA diagnostic to the forefront as a solution for the needs of MedAxiom’s cardiovascular community. This event will feature C-suite executives and decision-makers from leading hospital systems looking to improve quality metrics that our technology addresses head-on - readmissions, mortality and optimal resource use. These hospital systems recognize MedAxiom as the leader to introduce solutions which improve outcomes, reduce costs, and better the lives of patients,” said Michael Feldschuh, CEO and President of Daxor.

BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes including a reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and results in a 55% reduction in length of stay when done on admission (P<0.001). BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost of care.

Register for the conference HERE.

View the Daxor Industry Partner Page.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

About MedAxiom

MedAxiom, an ACC Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of 450+ cardiovascular organization members, thousands of administrators, clinicians and coders and 40+ industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience. For additional information, visit MedAxiom.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com

FAQ

What is Daxor Corporation's stock symbol?

Daxor Corporation's stock symbol is DXR.

What technology does Daxor Corporation showcase at the MedAxiom CV Transforum Fall’22 Conference?

Daxor Corporation showcases its blood volume analysis (BVA) technology at the conference.

When is the MedAxiom CV Transforum Fall’22 Conference?

The MedAxiom CV Transforum Fall’22 Conference is being held from October 6-8, 2022.

What are the clinical outcomes related to Daxor's BVA technology?

Daxor’s BVA technology has shown a 82% reduction in 30-day mortality and a 56% reduction in 30-day readmissions.

Who are the partners of Daxor Corporation?

Daxor Corporation has partnered with MedAxiom to promote its BVA technology.